Sexual & reproductive GnRH (native)
Gonadorelin
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- Also known as
- It Is and What
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Gonadorelin is a synthetic form of the natural reproductive hormone GnRH, used in wellness and men's-health settings as an add-on to testosterone therapy to help preserve fertility and testicular size. The strongest human data come from a different setting. In a 2021 meta-analysis of 420 men with congenital hypogonadotropic hypogonadism across seven studies, pulsatile GnRH began sperm production 5.3 months earlier than gonadotropin therapy (p = 0.004), with no significant difference in sperm concentration (p = 0.37) or pregnancy rate (p = 0.11). Direct evidence for the testosterone add-on use is limited, and there is no FDA-approved gonadorelin product for it.
At a glance
- FDA status
- Synthetic native GnRH; no current FDA-approved product for the TRT-adjunct use
- How it works
- Stimulates the pituitary to release the reproductive hormones LH and FSH
- Research
- Hormone mechanism is well established, but direct evidence for the TRT-adjunct use is limited
- Availability
- Supplied through compounding pharmacies
- Evidence strength
- Low research
Summary
Gonadorelin is a synthetic GnRH used as a testosterone therapy add-on. See how it works, how limited the evidence is, and where its FDA status stands.
What is gonadorelin?
Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH), the natural ten-amino acid hypothalamic hormone that controls the reproductive axis. Historically it had limited approvals for diagnostic testing and fertility induction, but those branded products have been discontinued. In wellness and men's-health settings it is used as an add-on to testosterone replacement therapy to help maintain fertility and testicular size, supplied through compounding. There is no current FDA-approved gonadorelin product for that use.
How does it work?
Given in pulses, GnRH stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which drive the testes to produce testosterone and sperm. This pulsatile mechanism is textbook physiology. A key nuance is that continuous, non-pulsatile exposure instead shuts the system down, so the fertility-preserving rationale depends on intermittent delivery and gonadorelin's very short duration of action. This describes the mechanism, separate from how well the specific add-on use is supported.
Is it FDA-approved?
Safety note
Status: Synthetic native GnRH; no current FDA-approved product for the TRT-adjunct use
Category: Wellness and performance · Primary body area: Sexual & reproductive
Not for this use. Gonadorelin's earlier approvals were for diagnostic and fertility-induction purposes, and those products have been discontinued; there is no current FDA-approved gonadorelin product for the testosterone-therapy add-on use, which is supplied through compounding. That places it in the same unsettled peptide-compounding environment as other non-approved peptides, with 2026 FDA advisory activity that is non-binding and no finalized rule.
What does the research show?
Editor’s note
Evidence strength: Low research
The hormone mechanism is well established, but there is sparse direct human evidence for the marketed testosterone-therapy add-on use, and there is no approved product for it.
The hormone mechanism is well established, but the specific use is thinly supported. Pulsatile GnRH has a recognized role in treating certain fertility and hormone-deficiency conditions. However, there is limited direct published human evidence for the specific "add-on to testosterone therapy to preserve fertility and testicular size" use; this application is largely practice-based and extrapolated rather than supported by dedicated controlled trials, and gonadorelin's short duration makes its effect delivery-dependent.
The best human data come from congenital hypogonadotropic hypogonadism, in which GnRH secretion or action fails from birth. A 2021 meta-analysis of 420 men across seven studies compared pulsatile GnRH with gonadotropin therapy:
| Outcome | Pulsatile GnRH vs gonadotropin therapy | p value |
|---|---|---|
| Start of sperm production | 5.3 months earlier | 0.004 |
| Sperm concentration | No significant difference | 0.37 |
| Pregnancy rates | No significant difference | 0.11 |
None of these men were on testosterone therapy, so the results do not show whether gonadorelin works as an add-on.
Sources: the physiology of GnRH stimulating LH and FSH is established in the endocrinology literature indexed on PubMed; and FDA records reflecting the discontinued gonadorelin products. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
Compare every peptide’s status in the peptide regulatory status database
More for Sexual & reproductive
View all sexual & reproductive peptides →- FDA-approved Sexual & reproductive
Cetrorelix
Cetrorelix is a synthetic ten-amino acid peptide that blocks the GnRH receptor in the pituitary gland, shutting down the hormone signals that would otherwise trigger early ovulation. It is FDA-approved as Cetrotide, a subcutaneous injection used during IVF to stop a premature LH surge so that eggs can mature and be collected on schedule. It remains a standard part of modern IVF stimulation, valued for acting quickly and for lowering the risk of ovarian hyperstimulation compared with older protocols.
- FDA-approved Sexual & reproductive
Degarelix
Degarelix (sold as Firmagon) is a synthetic decapeptide that blocks the gonadotropin-releasing hormone receptor, dropping testosterone to castrate levels within a few days and without the initial surge seen with older hormone drugs. It is used to treat advanced prostate cancer and lowers testosterone to castrate levels faster than the agonist leuprolide. It has been FDA-approved in the U.S. since 2008 and is given as a monthly subcutaneous injection.
- FDA-approved Sexual & reproductive
Ganirelix
Ganirelix (originally approved as Antagon) is a synthetic decapeptide that blocks the gonadotropin-releasing hormone receptor, used during fertility treatment to stop an egg from being released too early. Given once daily during ovarian stimulation, it prevents the premature luteinizing hormone surge that could otherwise disrupt an IVF cycle. It has been FDA-approved in the U.S. since 1999 and is given as a small daily subcutaneous injection.
- FDA-approved Sexual & reproductive
Goserelin
Goserelin (goserelin acetate, sold as Zoladex) is a synthetic decapeptide agonist of gonadotropin-releasing hormone delivered as a small implant that suppresses the body's production of testosterone and estrogen. It is used across prostate cancer, breast cancer, and endometriosis, and in one long-term breast-cancer trial it matched standard chemotherapy for survival in certain premenopausal women. It has been FDA-approved in the U.S. since 1989 and is given as a monthly or three-month depot implant.
- FDA-approved Sexual & reproductive
Histrelin
Histrelin (histrelin acetate, sold as Supprelin LA and formerly as Vantas) is a synthetic nonapeptide agonist of gonadotropin-releasing hormone delivered as a small implant that releases drug for about a year. It suppresses the pituitary and the sex hormones it controls, and is used for central precocious puberty in children; a second implant for advanced prostate cancer in adults was discontinued in 2021. The implant products have been FDA-approved in the U.S. since the mid-2000s, and one implant lasts roughly 12 months.
- FDA-approved Sexual & reproductive
Human-Chorionic-Gonadotropin
Human chorionic gonadotropin (hCG; FDA-approved injectable brands include Pregnyl and Novarel) is a placental hormone that acts like luteinizing hormone, triggering ovulation in women and testosterone production in men. It is used in fertility treatment, in male hypogonadotropic hypogonadism, and for undescended testicles in boys, and it is not approved for weight loss. In a Cochrane review of seven trials with 1,136 women, recombinant and urinary hCG gave similar ongoing pregnancy or live-birth rates (odds ratio 1.15, 95% confidence interval 0.89 to 1.49).